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RAPPORT DE SYNTHESE 
Androgen Dependence of Hirsutism, Acne, and Alopecia in Women. Retrospective Analysis of 
228 Patients lnvestigated for Hyperandrogenism. 
Dépendance aux androgènes de l'hirsutisme, l'acné et l'alopécie chez la femme. Analyse 
rétrospective de 228 patientes investiguées pour hyperandrogénie. 
L'hirsutisme, l'acné et l'alopécie chez la femme sont souvent associés à des troubles menstruels et à 
une production excessive d'androgènes, raison pour laquelle ces symptômes cutanés font l'objet 
d'évaluation endocrinienne. L'hyperandrogénie affecte 5 à 10 % des femmes en âge de reproduction 
et constitue un motif fréquent de consultation. Récemment, les sociétés d'endocrinologie ont émis des 
recommandations sur l'investigation et le traitement de l'hyperandrogénie. 
Longtemps confrontés à la demande de patientes souffrant d'hirsutisme, d'acné ou d'alopécie, nous 
avons décidé d'effectuer une approche diagnostique et thérapeutique comportant des dosages 
hormonaux et un traitement antiandrogénique. Un grand nombre de patientes a été ainsi étudié au fil 
des années. Les paramètres mesurés incluaient la testostérone plasmatique totale, l'androstènedione, 
le sulfate de déhydroépiandrostérone (DHEAS), la sex hormone-binding globulin (SHBG) et la 
testostérone salivaire. Cette dernière est considérée comme un bon reflet de la testostérone libre 
plasmatique, indépendamment des protéines de liaison. L'analyse rétrospective des dossiers nous a 
permis de comparer nos données avec celles de la littérature. 
Des 318 dossiers de patientes ayant consulté notre Service pour hirsutisme, acné ou alopécie 
pendant 6 ans, 228 ont pu être retenus pour une évaluation adéquate. Chez les patientes présentant 
ces symptômes de façon isolée, les taux d'androgènes et la prévalence de l'oligo-aménorhée étaient 
plus élevés en cas d'hirsutisme qu'en cas d'alopécie, avec des valeurs intermédiaires en cas d'acné. 
Aucun des androgènes mesurés ne permettait, à lui seul, d'identifier tous les cas d'hyperandrogénie, 
mais la testostérone salivaire a montré la meilleure corrélation positive avec l'hirsutisme, alors que la 
testostérone plasmatique totale montrait la moins bonne corrélation, et l'androstènedione, le DHEAS 
et la SHBG des corrélations intermédiaires (corrélation négative pour la SHBG). De plus, au cours du 
traitement antiandrogénique, la testostérone salivaire a montré l'abaissement proportionnel le plus 
marqué de tous les androgènes mesurés. Comparées aux patientes originaires d'Europe centrale, les 
patientes originaires d'Europe du sud consultaient avec des degrés d'hirsutisme supérieurs, mais 
aucune différence n'a été observée dans les corrélations entre l'hirsutisme et les taux hormonaux de 
ces deux groupes. En l'absence d'un nombre suffisant d'échographies ovariennes, la prévalence du 
syndrome des ovaires polykystiques a été probablement sous-estimée (63 patientes, 27.6 % des cas), 
au bénéfice du diagnostic d'hyperandrogénie avec eu ménorrhée (101, 44.3 %) ; les autres diagnostics 
étaient: androgènes normaux (51, 22.4%), SHBG basse isolée (7, 3.1 %), hyperplasie surrénalienne 
congénitale non-classique (4, 1.8%), et tumeur ovarienne (2, 0.9%). 
Nous avons comparé les divers traitements médicaux de l'hirsutisme publiés au cours des 25 
dernières années, quant à leur efficacité et leur coût. La sensibilisation à l'insuline avec metformin est 
moins efficace, mais aussi moins chère. L'anti-androgène flutamide et l'inhibiteur de la 5-a reductase 
finastéride figurent parmi les traitements les plus performants, mais ils sont aussi les plus chers. Le 
traitement anti-androgénique et de suppression hormonale avec acétate de cyprotérone et éthinyl-
oestradiol, utilisé dans cette étude, est également parmi les plus efficaces, tout en étant nettement 
moins cher. 
Cette étude est la première comparant directement les taux d'3ndrogènes et la prévalence de l'oligo-
aménorrhée dans les 3 symptômes cutanés d'hyperandrogénie, hirsutisme, acné et alopécie, et elle 
démontre leur différente dépendance aux androgènes. La salive apparaît comme un milieu de choix 
pour identifier ces patientes et la recommandation actuelle de doser la testostérone plasmatique totale 
en premier, pour distinguer l'hyperandrogénie de l'hirsutisme idiopathique, nous paraît inadéquate. 
Nous proposons, au contraire, d'abandonner ce dosage au profit de celui de la testostérone salivaire. 
Par ailleurs, notre étude infirme l'hypothèse d'une sensibilité cutanée accrue aux androgènes chez les 
femmes originaires du sud de l'Europe. Finalement, elle est la seule à comparer les effets cliniques, 
les changements biologiques et le coût annuel des traitements publiés de l'hirsutisme. 
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Abstract: Hirsutism, acne, alopecia, and oligo-amenorrhea are clinical 
expressions of hyperandrogenism, one of the most frequent endocrine 
disorders in women of reproductive age. Women referred to our 
endocrine clinics for skin symptoms of hyperandrogenism underwent a 
laborat01y workup to evaluate hormone measurements and received 
antiandrogen therapy. We retrospectively analyzed the outcome of 228 
consecutive patients investigated over 6 years. 
Patients with hirsutism had higher levels of androstenedione, 
dehydroepiandrosterone sulfate (DHEAS), and salivary testosterone; 
lower levels of sex h01mone-binding globulin (SHBG); and a higher 
prevalence of oligo-amenorrhea than patients with alopecia, while 
patients with acne showed intermediate values. Hirsutism score 
correlated positively with androstenedione, DHEAS, and salivary 
testosterone, and correlated negatively with SHBG; salivary testosterone 
showed the highest correlation coefficient. Total testosterone was not 
significantly different among patients with hirsutism, alopecia, or acne, 
and did not significantly correlate with hirsutism score. Hirsutism and 
oligo-amenorrhea were the most sensitive symptoms of hyperandrogen-
ism, and no androgenic parameter alone allowed us Io identify al! cases 
of hyperandrogenism. 
Patients of central European origin sought consultation with milder 
hirsutism scores than patients of southern European origin. There was, 
however, no difference in the clinical-biological correlation between 
these groups, arguing against differences in skin sensitivity to androgens. 
Polycystic ovaiy syndrome, defined as hyperandrogenism (hirsutism 
or elevated androgens) and oligo-amenorrhea, was diagnosed in 63 
patients (27.6%), an underestimate compared with other reports that 
include systematic ovarian ultrasound studies. Neither pelvic ultrasound, 
used in a limited number of cases, nor the luteinizing hormone/follicle-
stimulating hormone ratio helped to distinguish patients with polycystic 
ovary syndrome from the other diagnostic groups. These included 
hyperandrogenism (hirsutism or elevated androgens) and eumenorrhea 
(101 patients; 44.3%); normal androgens (acne or alopecia and 
eumenorrhea) (51 patients; 22.4%); isolated low SHBG (7 patients; 
3.1 %); nonclassical congenital adrenal hyperplasia (4 patients; 1.8% of 
total, 4.9% of patients undergoing cosyntropin stimulation tests); and 
ovarian tumor (2 patients; 0.9%). 
Ethinylestradiol and high-dose cyproterone acetate treatment lowered 
the hirsutism score Io 53.5% ofbaseline at 1 year, and was also effective 
in treating acne and alopecia. The clinical benefit is ascribed to the 
peripheral antiandrogenic effect of cyproterone acetate as well as the 
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horrnone-suppressive effect of this combination. Salivary testosterone 
showed the most marked proportional decrease of ail the androgens 
under treatment. Cost-effectiveness and tolerance of ethinylestradiol and 
high-dose cyproterone acetate compared well with other antiandrogenic 
drug therapies for hirsutism. The less potent therapy with spironolactone 
only, a peripheral antiandrogen without hormone-suppressive effect, was 
effective in treating isolated alopecia in patients with normal androgens. 
(Medicine 2009;88: 32-45) 
Abbreviations: 17-0HP = 17-hydroxyprogesterone, DHEA = 
dehydroeplandrosterone, DHEAS = dehydroepiandrosterone'sulphate, 
FSH = follicle-stimulating hormone, LH = luteinizing hormone, 
NCAH = nonclassical congenital adrenal hyperplasia, SHBG = sex 
hormone-binding globulin. 
INTRODUCTION 
Hirsutism, acne, and scalp hair loss in women are a fre-
quent cause of referral to endocrine clinics, since they are often 
associated with menstrual abnormalities and are usually ascribed 
to hyperandrogenism.50 Hyperandrogenism is one of the most 
frequent endocrine disorders, considered to affect So/o-10% of 
reproductive-aged women in different regions of the world. 6 
Androgens are necessaiy for the physiologie development 
of the pilosebaceous unit. Under the action of androgens, villous 
hair becomes terminal hair in skin areas where women have 
considerably less hair than men. 14'38 Studies have demonstrated 
increased androgen production by the avaries and the adrenals of 
women with hirsutism.46 Androgens are also involved in the 
development of acne, a disorder of the pilosebaceous unit that 
occurs physiologically during the rise of androgen levels at the 
onset of puberty in both sexes.32•33 Acne can develop in adult 
women as a manifestation of hyperandrogenism, even in the 
absence of hirsutism.47 Androgen excess in women can also 
cause hair loss of the scalp region leading to alopecia; women 
with hyperandrogenism may present with alopecia, associated 
with acne and hirsutism or as an isolated skin symptom. 19 The 
elevated scalp sensitivity to androgens may be explained by 
the high concentration in this tissue of type 1 5a-reductase, 
the enzyme that converts testosterone into the more patent 
androgen dihydrotestosterone. 61 
Although it is assumed that women with skin symptoms of 
hyperandrogenism have an increased rate of ovarian and adrenal 
androgen production, 64 there is no good correlation between 
symptoms and circulating testosterone levels. One of the reasons 
for this poor correlation is that most total testosterone circulates 
bound to albumin and to sex ho1mone-binding globulin 
(SHBG), whereas free testosterone, which is supposed to be 
the major determinant of the hormonal action in peripheral 
tissues, constitutes only about 2% of total testosterone. More-
over, increased androgen production, as well as increased body 
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weight, results in decreased SHBG levels, and therefore mo-
derate increases in testosterone production may not be suffi-
cient to raise sernm total testosterone, particularly in overweight 
women.
13
·
27 
Under these conditions, free testosterone ma(i well 
be elevated and may show good clinical correlation, 1 but 
measuring it has limitations in te1ms of sensitivity, accuracy, 
and practicability.48•51 For that reason salivary testosterone 
has been proposed as a surrogate measurement for circulating 
free testosterone, 48 and has demonstrated a better correlation 
to the degree of hirsutism than total testosterone or SHBG.53 
Another reason for poor correlation is that conversion rates 
of androgen precursors dehydroepiandrosterone (DHEA), de-
hydroepiandrosterone sulfate (DHEAS), and androstenedi-
one, into testosterone and dihydrotestosterone, are not evaluated 
on clinical grounds although they may present important 
individual variations. 29 
Different pathogenetic mechanisms may play a role in ac-
ne and hirsutism. It has been shown that the dihydrotestoste-
rone metabolite 3a androstanediol and its glucuronide are 
produced in significantly smal!er amounts in women present-
ing with acne than in women presenting with hirsutism, despite 
identical total testosterone and dihydrotestosterone levels. 62 
This suggests that a different tissue response to androgens de-
termines the different clinical expressions of hyperandroge-
nism. Furthermore, in the case of acne, beyond androgen 
stimulation of sebaceous gland growth and sebum production, 
additional factors contribute to the formation of micro-
comedones, such as sebum clogging in hair follicles, coloniza-
tion with Propionibacterium acnes, and tissue inflammatory 
response. This may explain the poor correlation between symp-
tom severity and androgen levels. 2 The causes of hair loss in 
women can be multiple, and while hyperandrogenism is rare in 
dermatologie clinics,56 it is seen frequently in endocrine cli-
nics, 19 reflecting an obvious selection bias. 
Individual susceptibility and ethnie factors play arole in the 
clinical manifestations of hyperandrogenism. Studies in twins 
indicate that genetic factors markedly influence testosterone 
secretion and processing to dihydrotestosterone and to 3a-
androstanediol,37 and variants in the gene encoding for type 1 
5a-reductase, the predominant isoenzyme responsible for 
dihydrotestosterone formation in hair follicles, are associated 
with the degree of hirsutism in affected women.21 On the other 
hand, normal and hyperandrogenic women of different ethnie 
origins show differences in circulating androgens and urinary 
metabolites, suggesting ethnie differences in androgen secretion 
and action,31 ·65 although some of these observations may have 
been affected by environmental confounding factors. 55 
Notwithstanding the anticipated difficulty of obtaining a 
representative picture of the androgenic status of patients and 
forma! proof of the relevance of androgen levels to hirsutism, 
acne, and alopecia in women seeking medical advice for those 
symptoms, we considered it important to measure androgens 
in order to confirm the hormonal imbalance, to establish a diag-
nosis, and to make the appropriate therapeutic decisions. This 
has been our practice over the years. In the current study, we 
retrospectively reviewed the results of the endocrine workup 
and antiandrogen therapy carried out in women referred to 
our endocrine clinics for hirsutism, acne, and hair loss and/or 
alopecia. 
PATIENTS AND METHODS 
We reviewed the records of 318 consecutive nonmenopau-
sal adult women, who consulted our endocrine clinics for 
hirsutism, acne, and diffuse nonscarring hair loss and/or 
© 2009 Lippincott Williams & Wilkins 
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alopecia (hereafter termed alopecia), suspected to be due to 
hyperandrogenism. Most patients were referred by general 
practitioners. We limited the study to the referral period between 
Januaiy 1991 and April 1997, since in the following years 
hospital records lacked sufficient family data on new patients for 
an appropria te assessment of their regional origin. To facilitate 
the retrospective analysis, we created a database (Microsoft 
Access 2.0) and entered the clinical and laboratoty data. 
Clinical Features 
Clinical features included the regional distribution of body 
hair to establish a total hirsutism score according to Ferriman 
and Gal!wey. 18 Only terminal hair was considered, and none of 
the patients was taking drngs known to induce generalized 
hypertrichosis, such as glucoc01iicoids or antiepileptic drngs. 
The total hirsutism score is the sum of regional hair scores in 11 
areas of the skin, including the face, the trnnk, and the ex-
tremities, graded from 0 to 4. A hormonal hirsutism score in 9 
areas, excluding forearms and legs, was also defined on the 
assumption that hair growth in those locations was not androgen 
dependent.23 However in our experience, hair on forearms and 
legs is also increased in hirsute patients and decreases under 
antiandrogenic treatment, proving androgen dependence, and 
therefore we based our analysis on the total score. Patients were 
considered to be hirsute when they presented a total hirsutism 
score 2:9 according to Ferriman and Gallwey 18 (this corre-
sponded to a hormonal hirsutism score 2:5 in al! the patients). 
The presence or absence of acne and alopecia was recorded 
for al! patients, but no attempt was made to quantify acne, and 
the female or male pattern of alopecia was not systematically 
recorded. 30 Potential causes oftelogen effluvium, such as recent 
parturition, serious illness, or obvious nutritional deficiency, 
were rnled out in al! patients, but hidden iron deficiency was 
not systematically sought by measuring sernm ferritin and 
C-reactive protein. 
Regarding menstrual status, patients were considered to be 
eumenorrheic when they reported regular menses at normal 
intervals, and to be oligo-amenorrheic when they reported 
amenorrhea (absent menstrnal periods for 2:3 months), or 
oligomenorrhea (irregular menses with fewer than 9 menstrnal 
periods per year). 
At the initial evaluation and during follow-up, al! patients 
were systematically examined by 2 observers, one a physician 
with a background in interna! medicine undergoing endocrine 
training (approximately 50% were women over the period 
studied), and one of the authors (FG) as supervisor. Consensus 
on the hirsutism score, on the presence of acne or alopecia, and 
on the response to therapy was recorded. 
Hormone Laboratory Workup 
The hormone laboratory workup on the initial evaluation 
was performed in mid-follicular phase for patients with normal 
menstrnal periods, and during amenorrhea or in the absence of 
ovulation based on progesterone levels for patients with oligo-
amenorrhea. Hyperprolactinemia and ovarian failure were 
excluded as causes of amenorrhea. Two patients with hirsutism 
were excluded because of markedly elevated prolactin levels, 
ascribed to idiopathie hyperprolactinemia on eventual investiga-
tions, and none of the patients referred for hirsutism, acne, or 
alopecia had premature ovarian failure. None of the patients had 
clinical Cushing syndrome on first examination or on follow-up, 
but no systematic endocrine testing was performed to unveil 
occult Cushing syndrome. Al! patients with classical congenital 
adrenal hyperplasia who were seen in our adult endocrine clinics 
over the period studied had been on corticosteroid replacement 
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TABLE 1. Patient Estimation and Physician Assessment of 
Hirsutism, Acne, and Alopecia in 279 Patients* 
Condition 
Hirsutism 
Ac ne 
Alopecia 
Hirsutism and alopecia 
Hirsutism and acne 
Alopecia and acne 
No. of Patients With Condition 
By Patient 
Estimation 
111 
11 
77 
19 
45 
6 
By Physician 
Assessment 
80 
18 
67 
14 
61 
14 
Hirsutism, alopecia and acne 10 17 
Total no. of patients 279 271 
*As explained in text, 51 of 279 patients were eventually excluded 
from study. 
therapy since childhood and were not considere~ for inclus~o'.1 in 
the study; none of the patients include~ had a h1sto:y or c!t'.ucal 
examination consistent with classtcal congemtal adrenal 
hyperplasia. . 
The following hormonal data were evaluated for the 
purpose of this study: total testosterone, salivaiy testoster?ne, 
androstenedione, DHEAS, SHBG, luteinizing hormone/folltcle-
stimulating hormone (LH/FSH) ratio, and 17-hydrox~progester­
one (17-0HP), before and 60 minutes aft~r a 250 µg mtravenous 
cosyntropin-stimulating test. The followmg ass~y meth?ds we:e 
used: radioimmunoassay for serum androstenedtone (D.iagnost~c 
Systems Laboratories, USA), serum DHEAS (~tagno~ttc 
Systems Laboratories, USA), serum 17-0HP (CISbto. Intem~­
tional, France), and plasma total testos~erone. (Dtagnostt~ 
Products Corporation, USA); immunoradtometnc. assay .for 
sernm SHBG (Orion Diagnostica, Finland); and mJCroparttcle 
enzyme immunoassay IMX and AXSIM (Abbott, U~A) for 
sernm LH and FSH. For salivaty testoster~ne, saltva was 
collected by free salivation into polystyr~ne d1sposable tube~. 
After sample extraction with n-hexane-dtethy!-~ther, t~s.toster­
one was measured using a specific and senstttve rad101mmu-
Medicine • Volume 88, Number l, january 2009 
noassay developed in our laborat.01y and pr~vi?usly desc~bed,35 
with a mean inter-assay coefficient of vanatton of 8 .8 Yo on a 
salivaty pool of salivary testosterone 120 pmol/L. ~he re~eren~e 
intervals for ail the above methods were estabhshed m thts 
laboratory. Because of the retrospectiv~ nature of the study, not 
al! the data were available for each pattent. 
Ovarian Ultrasound Study 
In a limited number of cases, ovarian ultrasound st~dy was 
performed via the transabdominal route un der the superv1s1011 of 
one of the authors (JYM). Ovarian volume in mL was calculated 
with a simplified formula for an ellipsoid (1/2 x length.[c~] x 
width [cm] x thiclmess [cm]); ovarian ~t~oma was ~uantttat1vely 
estimated; and the number and disposition of fol!tcles or cysts 
were recorded. 
Skin Symptoms 
In 39 of the initial 318 patients, skin symptoms could n?t be 
assessed accurately from the data on recor.d, so those. patients 
were excluded from the study. In the remain~ng ~79 patients, the 
patient's estimation of the presence. ?f ~1rsut1sm, acne, and 
alopecia was compared with the phys1ctan s assessmen~ ~fthese 
symptoms. Patients tended to overestimate, or phys1c1ans to 
underestimate, the presence of hirsutism, whereas ~he re~erse 
occurred for acne (Table 1 ). For subsequ~nt analysts, p~t~ent,s 
were distributed for sldn symptoms accordmg to the phystctan s 
assessment. . . 
In 8 patients, no hirsutism, acne, or alopecta was ~tagnosed, 
so they were excluded from the study. Forty-three pat1e~ts were 
on oral contraception when they consulted for the first ttm~ and 
were also excluded from the study. The remaining 228 patients 
are described below. None of them had received any sex 
hormone treatment for at least 3 months before the study, and 
none was pregnant. In al! cases, skin sympt.oms were constdered 
"patient-important," since previous cosmett~ measur~s .had been 
judged insufficient by patients and referrmg phystctans, and 
further investigation was sought. 
Antiandrogenic Treatment 
Patient follow-up during antiandrogenic treatment was 
recorded. Patients with hirsutism and/or acne were offered 
TABLE 2. Clinical and Biological Characteristics of Patients With lsolated Hirsutism, Acne, or Alopecia 
Age (yr) 
BMI (kg/m2) 
T (nmol/L) 
Ts (pmol/L) 
A (nmol/L) 
DHEAS (µmol/L) 
SHBG (nmol/L) 
No. of patients with any abnormal values 
No. of patients with oligo-amenorrhea 
Hirsutism (n - 64) Acne (n - 16) Alopecia (n 53) 
30.3 ± 12.6t (64) 29.8 + 7.6* (16) 36.2 + 11.3 (53) 
24.7 ± 5.1 (57) 24.0 ± 5.1 (16) 24.8 ± 6.7 (49) 
1.6 ± 0.7 (60) 1.6 ± 0.7 (16) 1.4 ± 0.7 (40) 
78.l ± 31.4t (53) 72.8 ± 21.7 (16) 61.4 ± 31.7 (47) 
8.8 ± 4.2t (57) 7.9 ± 3.3 (14) 6.4 ± 3.6 (48) 
8.0 ± 3.3t (56) 7.4 ± 3.3 (14) 5.7 ± 2.7 (49) 
33.4 ± 17.4t (56) 41.9 ± 17.5 (14) 44.0 ± 17.8 (42) 
48/64 :j: 9/16 17 /53 
26/62§ 6/l 6:j: 4/43 
Mean± SD (no. of patients). Patients with mixed skin symptoms (n 95) not shown. 
*P < 0.05. 
t P < 0.01 vs. Alopecia, Student t test. 
:j:P < 0.05. 
Reference Interval 
0.7-2.8 
15-100 
3.5-10.0 
2.2-9.6 
30-80 
§P < 0.01 vs. Alopecia, x2. d' . DHEAS dehydroepiandrosterone sulfate; Abbreviations: BMI, body mass index; T, total testosterone; Ts, salivaiy testosterone; A, androstene 1one, , 
SHBG, sex hormone-binding globulin. 
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TABLE 3. Clinical and Biological Characteristics of Patients According to the Presence or Absence of Hirsutism 
Hirsutism (Isolated or With Acne 
aud/or Alopecia) (n = 148) 
No Hirsutism (Acne and/or 
Alopecia) (n = 80) 
Reference 
Interval 
Age (yr) 
BMI (kg/m2) 
T (nmol/L) 
Ts (pmol/L) 
A (nmol/L) 
DHEAS (µmol/L) 
SHBG (nmol/L) 
No. of patients with any abnormal values 
No. of patients with oligo-amenorrhea 
Mean± SD (no. of patients). 
*P < 0.01, Student t test. 
tP < 0.05. 
tP < 0.01, x2, vs. No hirsutism. 
Abbreviations: see previous table. 
28.4 ± 11.3* (148) 
24.3 ± 5.1 (148) 
1.7 ± 0.8 (144) 
81.4 ± 33.6* (132) 
9.0 ± 3.9* (141) 
7 .9 ± 3.5* (139) 
34.8 ± 18.3* (131) 
109/148t 
57/146t 
symptomatic antiandrogenic treatment with ethinylestradiol and 
high-dose cyproterone acetate in a "reverse cycle" sequence,22 
consisting of ethinylestradiol 35 µg/day for 21 consecutive days, 
cyproterone acetate 100 mg/day, during the first 11 days of 
ethinylestradiol administration, and a drng-free interval of 7 
days, for 28-day cycles. The general practice was to halve the 
daily dose of cyproterone acetate after 6 cycles, with no attempt 
to treat acne with retinoic acid derivatives until then. To monitor 
treatment, patients were asked to report at 3-month intervals, 
l month apart from the previous depilation to verify the effect on 
hirsutism, acne, and alopecia. 
Patients with isolated alopecia and no biological hyperan-
drogenism were offered treatment with spironolactone, at doses 
gradually increasing up to 1 OO mg/day, and the effect was 
evaluated at 1- to 3-month intervals. On control visits, patients 
were interviewed for drug tolerance. 
All patients who were prescribed antiandrogenic therapy 
were initially followed for tolerance in our clinics, but approx-
imately 40% of them eventually pursued the treatment un-
der the surveillance of referring physicians, and monitoring 
for efficacy was not in our records. Patients with ovmian tu-
mor (see below) were offered surgical treatment. 
RESULTS 
Clinical Hyperandrogenism 
To ascertain the androgen dependence of hirsutism, acne, 
and alopecia, we compared androgen and SHBG levels in 
patients presenting with 1 ofthese symptoms alone (Table 2). No 
TABLE 4. Linear Correlation With Total Hirsutism Score* 
33.6 ± 11.9 (80) 
24.4 ± 6.4 (79) 
1.5 ± 0.7 (67) 
63.7 ± 27.4 (73) 
6.7 ± 3.3 (72) 
6.2 ± 2.9 (72) 
44.4 ± 19. l (66) 
26/80 
13/72 
0.7-2.8 
15-100 
3.5-10.0 
2.2-9.6 
30-80 
significant differences were observed in total testosterone values. 
Higher levels of salivary testosterone, androstenedione, and 
DHEAS, and lower levels of SHBG were observed in patients 
with isolated hirsutism compared to patients with isolated 
alopecia, whereas patients with isolated acne showed inter-
mediate values not significantly different from the other 2 
groups. Differences in SHBG were not explained by differences 
in body mass index. The proportion of patients with 1 or more 
abnormal values was higher in the hirsutism group than in the 
alopecia group, and an intermediate, not significantly different 
proportion was observed in the acne group. Although moder-
ately older, patients with alopecia had oligo-amenorrhea less 
often than patients with hirsutism or acne. 
From these data we concluded that hirsutism was more 
closely associated with biological hyperandrogenism than 
alopecia and acne. Furthermore, we compared the clinical and 
biological characteristics of patients with hirsutism, isolated or 
in combination with acne and/or alopecia, with those of patients 
presenting with acne and/or alopecia but no hirsutism (Table 3). 
Patients with hirsutism had significantly higher levels of salivary 
testosterone, androstenedione, and DHEAS; had lower levels of 
SHBG; and had a higher prevalence of abnormal values and of 
oligo-amenorrhea than patients without hirsutism. 
Biological Hyperandrogenism 
We evaluated the different androgens and SHBG as 
biological markers of clinical hyperandrogenism by comparing 
them with the quantitative hirsutism score. Salivary testosterone, 
androstenedione, and DHEAS showed a significant positive 
Hormonal Hirsutism Scoret T (nmol/L) Ts (pmol/L) A (nmol/L) DHEAS (µmol/L) SHBG (nmol/L) 
Correlation coefficient 0.993 0.137 0.309 0.249 0.280 -0.289 
No. of pairs 228 211 205 213 211 197 
PValue <0.001 NS <0.001 <0.001 <0.001 <0.001 
*Total hirsutism score is the sum of terminal hair scores in 11 areas of the skin, graded from 0 to 4, according to Ferriman and Gallwey. 18 
tHormonal hirsutism score is the total hirsutism score minus the scores in forearms and legs.23 Hirsutism in women was defined as a total hirsutism 
score 2:9. 
Abbreviations: see previous table. 
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TABLE 5. Patients Presenting With Elevated Androgens or 
Decreased SHBG 
Increased T 
Increased Ts 
Increased A 
Increased DHEAS 
Decreased SHBG 
Any abnormality 
Hirsutism (n = 148) 
No.(%) 
10/144 (6.9) 
32/132 (24.2) 
47/141 (33.3)* 
38/139 (27.3)* 
66/131 (50.4)* 
109/148 (73.6)t 
No Hirsutism (n = 80) 
No.(%) 
4/67 (6.0) 
8/73 (11.0) 
9172 (12.5) 
9172 (12.5) 
18/66 (27.3) 
26/80 (32.5) 
Pat~ents in the "No hirsutism group" presented with acne and/or 
alopecia. 
*P < 0.05. 
tP < 0.01, x2, VS. No hirsutism. 
Abbreviations: See previous tables. 
c~rrelatio~, an? SHBG showed a significant negative correlation 
w1~h t~e hirsutism score, whereas total testosterone did not show 
a s1gmficant correlation (Table 4). Salivmy testosterone had the 
highest correlation coefficient with hirsutism score. Hirsute and 
nonhirsute patients displaying elevated androgens or low SHBG 
l~vels. are shown in Table 5. Significantly more patients with 
hll'sut1sm had elevated androstenedione and DHEAS, lowered 
~H~G, or any of the above, than patients without hirsutism. A 
s1.1mlar trend was observed for salivary testosterone although it 
dtd not reach statistical significance, whereas total testosterone 
was elevated in a small, similar proportion of patients with and 
without hirsutism. 
.Although differences in SHBG were apparently unrelated 
to di~erences in body mass index (see Table 3), to avoid a 
pote~ttal confounding factor low SHBG values were not 
constdered as defining biological hyperandrogenism, and the 
presence of elevated androgens was required. Under this 
definition, "idiopathie hirsutism," which implies normal an-
dro.gens a~d e~1menorrhea, occurred in 50 of 146 (34%) 
p~tlen!s wtth hll'sutism, including 22 of 62 (35.5%) patients 
w1th 1solated hitsutism. Similarly, "idiopathie acne and/or 
alopecia" occurred in 49 of 72 (68%) patients including 6 of 
16 (37:5%) with isolated acne and 31 of 43 (72%) with isolated 
alopec1a. 
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Regional Origin of Patients 
. In most. cas.es, the patient's regional origin could be es-
tab~1shed taking mto account the origin of both parents. The 2 
mam groups were patients originating principally from Switzer-
land and France (hereafter te1med central Europe n = 142) or 
from ltaly, Spain, and Portugal (hereafter ter~ed southern 
Europe~ n = 67). We compared the clinical and biological char-
a?tenstlcs o: these 2 main groups. There were no significant 
dt~~rences m the proportion of patients of central European 
0~1g111. compared with southern European origin regarding 
hirs.uttsm (59.2% vs. 67.2%, respectively) or acne and/or alo-
pecta (40.8% vs. 32.8%, respectively). Although women from 
central Europe tended to consult with milder hirsutism scores 
t~an ~omen. from southern Europe, for a similar degree of 
hll'suttsm their hormone levels were similar (Table 6). 
Diagnosis 
For diagnostic purposes, "hyperandrogenism" in premen-
opaus~l women was defined as the presence of hirsutism 
( cons1de:ed,, here as synonymous with "clinical hyper-
androgemsm ) and/or elevated androgen levels ("biological 
hy~erandrogenism," defined as "hyperandrogenemia or elevated 
sahvary testosterone"), independent of SHBG levels and of the 
menstlual status. 
Patients were distributed in the following 6 diagnostic 
groups (Table 7): 
1) Hyperandrogenism and eumenorrhea (n = 101). 
2) Hyperandrogenism and oligo-amenorrhea (n = 63). 
3) N?rmal androgens (n = 51). This group consisted of patients 
wtth acne an<l'.or alopecia but no hirsutism or biological 
hyperandrogemsm (9 oligo-amenorrheic and 42 eumenor-
rhe!c pati~nts). To avoid the SHBG confounding factor, 
patients w1th low SHBG were not included in this group. 
4) Is?lated low SHBG (n = 7). This group consisted of patients 
wtth acne and/or alopecia and low SHBG but no hirsutism 
or biological hyperandrogenism (2 oligo-amenorrheic and 5 
eumenorrheic patients). 
5) Nonclassical (late-onset) congenital adrenal hyperplasia5 
(NCAH) (n = 4). This was diagnosed when 17-0HP was 
2'.30 nmol/L 60 min after 250 µg intravenous cosyntropin 
(2. patients originat~d from southern Europe and 2 from the 
Middle East; 3 patients presented with hirsutism and acne 
and 1 with hirsutism; 3 had normal menses and 1 had chronic 
anovulation). 
TABLE 6. Androgens and SHBG Levels in Patients With Hirsutism, According to Regional Origin in Europe 
Degree of Hfrsutism 
Central European Origin 
Moderate (n = 41) Severe (n = 43) 
Total score 11.2 ± 2.2 (41) 19.8 ± 5.3t (43) 
Hormonal score 7 6 + 1 4 (41) 
. - . 15.2 ± 4.4t (43) 
T (nmol/L) 1.5 ± 0.8 (39) 1.7 ± 0.8 (42) 
Ts (pmol/L) 66.7 ± 30.0 (39) 87.3 ± 39.3* (35) 
A (nmol/L) 7.6 ± 3.6 (40) 9.0 ± 4.6 (42) 
DHEAS (µmol/L) 7.1 ± 3.1 (38) 8.4 ± 3.8 (41) 
SHBG (nmol/L) 39.2 ± 18.7 (35) 32.6 + 17.4 (34) 
For abbreviations and reference intervals, see previous tables. 
Southern European Origin 
Modemte (n 11) Severe (n 34) 
10.2 ± 1.6 (11) 
7.2 ± 1.7 (11) 
1.6 ± 1.0 (9) 
62.2 ± 22.0 (10) 
7.2 ± 2.5 (8) 
8.0 ± 3.1 (8) 
37.9 + 22.8 (9) 
21.8 ± 5.2t (34) 
16.8 ± 4.7t (34) 
1.8 ± 0.9 (34) 
89.4 ± 32.5* (33) 
9.3 ± 3.6 (34) 
7.8 ± 3.5 (34) 
34.5 + 19 .3 (32) 
Mean± SD (no. of patients). Moderate degree ofhirsutism =total score 9-12· Severe degree ofhirsutism =total score 16--32 
*P<0.05. ' . 
tP = 0.01 vs. Moderate within the same regional origin group, Student t test. 
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. . . . Patients Presenting With Hirsutism and/or Acne and/or Alopecia 
Hormone Levels Accordmg to D1agnos1s m . TABLE 7. 
Hyperandrogenism 
and Eumenorrhea 
(n 101) 
Hyperandrogenism and Normal 
Oligo-Amenonhea/ Androgens Isolated Low SHBG (n = 7) 
Ovarrnn 
Tumor 
(n = 2) 
PCOS (n 63) (n 51) 
30.0 + 12.6til (7) 
1.1 ± 0.2 (7) 
63.8 ± 12.7 (5) 
5.2 ± 1.1 (7) 
5.5 ± 2.5 (6) 
20.5 ± 5.4 (7) 
1.0 ± 0.3 (3) 
3.9 ± 3.6 (3) 
NCAH (n= 4) 
22.6 + 2.0 (4) 25.2, 23.5 (2) 
BMI (kg/m2) 23.9 ± 4.3 (101) 
1.6 ± 0.8§ (99) 
78.0 ± 32.7*§ (92) 
8.4 ± 3.8t§ (96) 
7.9 ± 3.1§ (95) 
35.6 ± 19.7§ (92) 
1.6 ± 1.0 (71) 
3.0 ± 1.9 (43) 
24.9 + 5.7 (63) 23.6 + 5.6 (44) 
1.8 ± 0.8§ (62) 1.2 ± 0.5 (42) 1.5 ± 0.3 (4) 120.3 ± 12.7 (4) 
10.8 ± 1.5 (4) 
9.6 ± 4.8 (4) 
47.0, 49.0 (2) 
14.6, 18.2 (2) 
294, 403 (2) 
5.2, 4.5 (2) 
2.0, 0.6 (2) 
91.l ± 32.5§ (56) 55.5 ± 18.7 (51) 
10.2 ± 3.9§ (61) 5.6 ± 1.7 (45) 
T (nmol/L) 
Ts (pmol/L) 
A (nmol/L) 
DHEAS (µmol/L) 
SHBG (nmol/L) 
LHIFSH 
8.1 ± 3.9§ (59) 5.1 ± 2.4 (46) 
34.2 ± 17.0§ (53) 59.1 ± 20.2 (47) 
24.0, 19.0 (2) 
1.6 ± 1.0 ( 48) 1.3 ± 1.0 (27) 6.6 ± 2.9 (4) 9.5, 1.0 (2) 
Basal 17-0HP 
3.5 ± 2.2 (30) 1.2 ± 0.2 (3) 
(nmol/L) 
7.8 + 3.2 (43) 7.1 ± 3.1 (30) 5.4 ± 2.9 (3) 
7.7 ± 3.2 (3) 82.9 ± 64.2 (4) 12.5, 6.7 (2) 
60-min 17-0HP 
(nmol/L) . 
Mean± SD (no. of patients). Diagnosis groups defined m text. 
*P < 0.05. 
tP < 0.005 vs. Hyperandrogenism and oligo-amenorrhea. 
tP < 0.05. 
§P < 0.001 vs. Normal androgens. . ~p < 0.05 vs. Hyperandrogenism and eumenorrhea, Stude~t .t '.est. . NCAH nonclassical congenital adrenal hyperplasia; PCOS, pol~c~sttc 
Abbreviations: FSH, follicle-stimulating hormone; LfiH, lute1~1~11;,1f~~~:a:~1 mid-fohicular phase 17-0HP: 1.0-4.0 nmol/L. For other abbreviatlons 
d . 17 OHP 17-hydroxyprogesterone. Re erence met ' ovary syn rome, - , . 
and reference intervals, see prev1ous tables. 
. t (n - 2) (1 patient presented with hirsutism, the 6) Ovanan umor - . . h ) 
other with alopecia, and both w1th amenorr ea . 
Considering al\ these diagnoses together: patients w~th 
h perandrogenism had a higher pre~alence of ohg~-ameno~rl ~~ 
(?5 of 170; 44.1 %) than patients wtth normal androgens ( 
58· 19.0%; p < 0.02, x2). . . -
' The 63 patients with hyperandroge111sm and oltgo-.ameno: 
. . fi h d' sis of polycysttc ovarv 
rhea met the cntena or t e rngno . . 02 
·d· t the Rotterdam consensus defimtton, 
syndrome accor mg o · t' ligo 
which requires at least 2 of the following ~ char~ctens tes: o . -
or anovulation, clinical and/or ?iochem1cal s1gns of {1ypera~d 
drogenism and polycystic ovanan morphology on u trasot\ 1 
sh1dy (and exclusion of other etiol?gies suc~ as ~o~~~~~: 
adrenal hyperplasia, androgen-secretmg tum~rst a? th stud~ 
ndrome) However only 46 of the 228 patten s m. e ~d pelvic ~ltrasound, including the 40 patients ~hown ~ T~bl~ 8 
and owing to insufficient data, it was not possible to . eterm1~~ wh~ther in the other diagnostic groups there were pat~nts ·~1~ 
ol c stic ovarian morphology who would also meet t e en ~na 
p f;o0cystic ovary syndrome. Patients in the hyperandroge111sm 
o nd oligo-amenorrhea group had higher salivaiy testos~erone ~nd androstenedione levels than patients in the hyperan~r~~en­
ism and eumenorrhea group (see Table 7), and patients m t' e~e 
2 rou s showed significantly lower SHBG levels th~n pa ten s 
in gthe ~ormal androgens group (and by definition, ~·1gher total 
testosterone, salivary testosterone, andr?st~ne lO~~ffi ~nn­
DHEAS levels). However, there were no s1gmficant . t ere 
s amon these 3 groups regarding mean LHIFSH rat10, num-
ce f gt. t with LH/FSH >2 or > 1 (not shown), mean 
ber o pa 1en s · h l t d basal b 1 17 OHP levels number of patients w1t e eva e 
1 ~~~HP -(not shown), and ultrasound appearance of the ava-
ries (see Table 8). . ·fi d ·n 85 patients. 
The cosyntropm test was per orme t l/L were 
Cosyntropin-stimulated 17-0HP levels >30 nmo 
© 2009 Lippincoft Williams & Willdns 
observed in the 4 patients with N~AH by definition, whereas 
in the remaining diagnostic categones the level was <16 n:nol/~. 
b 1 17 OHP levels above normal were observed m However, asa - d' d on the 
onl 3 of the 4 patients in whom NCAH was rngnose . 
basts of the test, whereas similarly elevated basal leve~~nbl 7t~! 
the remaining 81 patients were not co?fi~med as NC y . 
cosyntropin test (these patients are d1stn?uted amongd' 4 theà 
d. ) The 2 patients with ovanan h1mor tsp aye rngnoses . d 6 t' the 
strikingly high total testosterone values, 5 an 1~~~ d 
l ll.1n1't 1'nd1'cating tumor hyperandrogenemrn, an upper norma ' d 4 · th 
similarly high salivary testosterone values, 3 an ttmes e 
upper normal limit. 
Antiandrogenic Treatment . . , 
Treatment efficacy was assessed ba~ed o, n phys1crnns 
d t ts estimation of evaluation of hirsutism scores, an on pa ten 
acne and alopecia. t . t 
Ethin lestradiol and high-dose cyprot~rone ~cet~te i.ea -
Yd . . t d to 124 of the 148 patients with htrsutlsm, ment was a m1111s ere f h 27 f nts 
isolated or with acne and/or alopecia, and to 20 ° t e h' P~ tet. 
with acne, isolated or with alopecia. T~e e~ect of et my es ra-. 
diol and cyproterone acetate on the lmsuttsm score after 3 or 
TABLE 8. Ovarian Characteristi.cs From Transabdo.minal 
Ultrasound Study in Patients W1th Hyperandrogernsm 
Characteristic 
Volume (mL) 
No. of follicles 
Stroma(%) 
Mean+ SD. 
Hyperandrogenism 
and Eumenorrhea 
(n = 15) 
9.4 ± 4.8 
3.5±3.5 
78 + 19 
Hyperandrogenism and 
Oligo-Amenorrhea 
(n = 25) 
10.1±4.1 
4.6 ± 4.3 
73 ± 22 
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TABLE 9. Effect of Ethinylestradiol and High-Dose Cyproterone Acetate Treatment on Hirsutism Score 
Months on Treatment 
Baseline 3 6 9 12 
Hirsutism score 18.3 ± 6.3 (74) 13.2 ± 6.6* (74) 11.6 ± 6.4* (54) 10.6 ± 5.5*t (38) 9 .8 ± 4.4 *t (30) 
Patients from the diagnostic groups Hyperandrogenism and eumenorrhea, and Hyperandrogenism and oligo-amenorrhea. Baseline hirsutism score 
range: 10-35. 
Mean± SD (no. of patients). 
*P < 0.01 vs. baseline. 
tP < 0.05 and tP < 0.01 vs. 3 mo, Student t test. 
more months was recorded in 74 patients, 42 eumenorrheic and 
32 oligo-amenorrheic (Table 9). The hirsutism score decreased 
progressively in ail patients followed in our clinics, with a 
significant decrease apparent at 3 months, and a value of 53.5% 
of baseline at 1 year. On-treatment hormone values are com-
pared to pre-treatment values in Table 1 O. Ali androgens de-
creased significantly, the most marked proportional decrease 
being that of salivary testosterone and the least being that of 
DHEAS; at the same time, SHBG showed a fourfold increase. 
No significant correlation was found between baseline andro-
gens or SHBG and the decrease of the hirsutism score during 
treatment. Acne improved in 40 of the 47 patients, with or 
without hirsutism, in whom the response was evaluated after 3 or 
more months, based on patients' estimation (26 hyperandrogenic 
eumenorrhea, 15 hyperandrogenic oligo-amenorrhea, 5 normal 
androgens, and 1 NCAH). Furthermore, 16 of 24 patients who 
were not complaining of acne, and were not considered as 
having acne on the initial evaluation, reported "improvement of 
acne" during ethinylestradiol and high-dose cyproterone acetate 
treatment. Alopecia under this treatment was reported to be 
improved by 16 of26 patients, unchanged by 7, and worsened by 
3 patients. 
Spironolactone was administered to 40 of the 53 patients 
presenting with isolated alopecia, and follow-up for treatment 
efficacy was recorded in 22 of them. Twelve patients reported 
improvement, 8 no change, and 2 reported worsening. Six of the 
patients who showed no change reported improvement on 
ethinylestradiol and high-dose cyproterone acetate added to 
spironolactone. 
One of the 2 patients with the diagnosis of ovarian tumor 
underwent successful surgical ablation of a small Sertoli-Leydig 
ce\\ tumor. The other patient refused surgical exploration and 
was lost to follow-up. 
Ninety-five of the 124 patients treated with ethinylestradiol 
and cyproterone acetate showed good tolerance to treatment, 
while 11 complained ofbreast tenderness, 10 ofheadache, and 8 
of heavy legs. These symptoms usually occurred at the 
beginning of treatment and subsided as treatment went on, and 
no treatment discontinuation was recorded in this retrospective 
evaluation. Absent or irregular menstrual response to drug 
withdrawal between cycles was not systematically recorded so 
no precise figures can be given here, but, in the authors' 
experience, this occurs in a limited number of patients, relatively 
ove1weight, and subsides after cyproterone acetate dose halving. 
Inter-menstrual bleeding was reported by 1 patient on spiro-
nolactone only. 
DISCUSSION 
Patients referred to our endocrine clinics for cutaneous 
symptoms ofhyperandrogenism were evaluated and treated with 
38 
antiandrogenic drugs on the basis that these symptoms were of 
subjective, esthetic, and social impo1iance to them. On the initial 
evaluation and on the follow-up, a relatively large number of 
hormones were measured, and this rendered meaningful a study 
on the apparent androgen dependence of hirsutism, acne, or 
alopecia, on the yield of individual hormone measurements to 
disclose hyperandrogenism, and on response to therapy. 
Although some of the observers changed over the years, 
consistency of clinical data throughout the study was guaranteed 
by the supervision of ail cases by one of the authors (FG). The 
main limitation of the study, inherent to its retrospective nature, 
is that data are missing, particularly on ovarian ultrasound. 
Importance of Skin Symptoms to Patients 
The discordant opinions between patients and physicians 
regarding the presence ofskin symptoms il\ustrates the "patient-
importance" ofthese symptoms, and suggests that women living 
in our community tolerate excess body hair and alopecia less 
well than acne. The elevated prevalence of oligo-amenorrhea in 
women with hirsutism ( 42% in the case of isolated hirsutism) 
may be an additional reason to seek medical advice, but this does 
not apply to those with isolated alopecia, since only 9% ofthose 
patients presented with menstrual disturbances. Social and 
cultural factors may also be involved, as suggested by the trend 
that women of central European origin consulted with milder 
hirsutism scores than women of southern European origin. In 
this context, it is interesting to note the absence of discrepancies 
in the clinical-biological correlation between these 2 groups, 
arguing against differences in skin sensitivity to androgens. 
Although these observations on hirsute patients do not 
necessarily apply to the population at large, they speak against 
the hypothesis that southern European women are more skin-
sensitive to androgens than central European women. 
TABLE 10. Hormone Changes During Treatment With 
Ethinylestradiol and High-Dose Cyproterone Acetate 
Percentage 
Baseline Treatment Change 
T (nmol/L) (28) 2.1±0.9 1.4 ± 0.7* -33.3 
Ts pmol/L) (32) 109.8 ± 50.4 50.4 ± 26.5* -54.1 
A (nmol/L) (35) 10.8 ± 3.5 6.1 ± 2.1 * -41.5 
DHEAS (µmol/L) (30) 10.0 ± 4.7 7.1 ±3.1* -29.0 
SHBG (nmol/L) (35) 28.8 ± 14.8 122.9 ± 52.0* 326.7 
Mean± SD (no. of patients). 
* P < 0.01 vs. Baseline, Student t test. 
Abbreviations and reference intervals: see previous tables. 
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Clinical Hyperandrogenism 
The higher androgen levels and increased incidence of 
oligo-amenorrhea in patients with hirsutism indicate that this 
symptom is more androgen dependent than acne and alopecia. 
Nevertheless, 26% of our patients with isolated alopecia had 
elevated androgen levels, a figure that is lower than the 
percentage of women with isolated hirsutism (76.5%), but 
higher than the figures usually reported in dermatologie series. 
Indeed, due to the low yield of androgens measured in patients 
with isolated nonscarring alopecia, de1matologists recommend 
performing those analyses only if additional symptoms such as 
menstrnal disturbances are present.43 Had we followed that 
recommendation, hyperandrogenism would have remained 
undiagnosed in 6 of the 10 patients presenting with eumenorrhea 
and isolated alopecia who did have elevated androgens. 
Unidentified selection bias in patients referred to endocrine 
clinics might explain the higher incidence ofhyperandrogenism 
in our patients with isolated alopecia. Moreover, if iron 
deficiency had been systematically sought and such patients 
excluded from the analysis, the proportion of women with 
isolated alopecia and hyperandrogenism might have been higher. 
Due to increasing awareness of the role of decreased iron stores 
in diffuse alopecia, screening these patients for low ferritin with 
normal C-reactive protein has become common practice in 
recent years. In the current study, however, the number of 
patients screened was too small to yield meaningful information. 
Patients with isolated acne had intermediate androgen and 
SHBG levels, not significantly different from patients with 
isolated hirsutism or alopecia, indicating intermediate androgen 
dependence of acne. 
To our knowledge, this is the first study directly comparing 
the prevalence of elevated androgens and oligo-amenorrhea in 
ail 3 skin symptoms of hyperandrogenism: hirsutism, acne, and 
alopecia. In Table 11 we compare our results with the experience 
of others. Sorne large studies on polycystic ovary syndrome 
include data on hirsutism that cannot be analyzed separately.7•11 
When direct comparison for skin symptoms was possible in 
published work, women with hirsutism disclosed more often 
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hyperandrogenism and oligo-amenorrhea than women with 
acne47•62 or alopecia, 19 similar to the findings in the current 
study. The high prevalence of oligo-amenorrhea in some studies 
reflects selection bias, since menstrnal or ovulatory abn01mal-
ities were criteria sufficient for inclusion.6•44 
Biological Hyperandrogenism 
Severa! studies report androgen levels similar to those 
observed in the current study ( see Table 11 ), and repo1i that the 
prevalence of elevated free testosterone or elevated salivary 
testosterone is also higher than that of elevated total testosterone. 
Although salivary testosterone, androstenedione, DHEAS, 
and SHBG ail showed significant correlation with the hirsutism 
score in the current study, no single parameter was sufficient to 
identify all cases of hyperandrogenism. Measuring ail para-
meters yielded the highest proportion of patients with biological 
hyperandrogenism. Low SHBG values may result not only from 
increased androgen action, but also from adiposity and insulin 
resistance, and therefore caution should be exerted to interpret 
such values. 13 However, since our patients with and without 
hirsutism had identical body mass index, we interpreted the 
differences in SHBG as differences of androgenicity. The 
prevalence of idiopathie hirsutism, defined as normal androgens 
and eumenorrhea, was 34% in the current study, although it 
rarely exceeds 20% if hidden anovulation is taken into account 
as a marker of increased androgen action ( 40% of hirsute 
eumenorrheic women present hidden anovulation4). On the 
other hand, community-recruited asymptomatic women with the 
metabolic syndrome and a relatively high calculated free 
testosterone have oligomenorrhea more often than controls but 
not more skin symptoms, indicating that abnormal menses may 
be a particularly sensitive index of androgenicity. 28 
Contrary to the other parameters evaluated, circulating total 
testosterone did not significantly correlate with the hirsutism 
score, and showed poor sensitivity to identify hyperandrogen-
ism. The Endocrine Society guideline's recommendation36 that 
total testosterone should be measured as the first step to 
distinguish hyperandrogenism from idiopathie hirsutism does 
TABLE 12. Prevalence of Specific Diagnosis in Patients Presenting With Hirsutism, Present and Previous Reports 
First Author, Year 
Carmina, 2006 
Moghetti, 2000 
Ruutiainen, 1987 
Spritzer, 2000 
Present repmi 
Azziz, 2004 
Escobar-Morreale, 
2008 
Ref. No. of Patients 
Referral (% With 
Hirsutism) 
9 950 
40 40 
53 
57 
6 
16 
48 
46 
148 
873 
270 
Hirsutism (95) 
Hirsutism (1 OO) 
Hirsutism (100) 
Hirsutism (100) 
Hirsutism (1 OO) 
Hyperandrogenismt (75.5) 
Hyperandrogenismt 
(U nspecified) 
*Ovarian ultrasound study used for diagnosis. 
tOvarian ultrasound study not used for diagnosis. 
PCOS (%) NCAH (%) ASN (%) 
72.l * 4.3 0.1 ov 0.1 adr 
52.5t 
31.3t 
43.2t 
39.0t 
82.0t 
63.3t 
2.7if 
2.1 
2.2 
4.2 adr 
0.7 ov 
0.2 ov 
tincludes patients with oligo-amenorrhea or anovulation, independent of skin symptomns. 
§Unspecified number of patients with NCAH excluded from study. 
if4. 7 of all patients in the study undergoing the cosyntropin test. 
Comments 
NCAH deliberately 
excluded from study§ 
NCAH deliberately 
excluded from study§ 
0.7% CAH 3.8% 
HA IRAN 
Abbreviations: ASN, androgen-secreting neoplasm (ov = ovarian, adr = adrenal); CAH, classical congenital adrenal hyperplasia; HAIRAN, 
hyperandrogenic insulin-resistant acanthosis nigricans; NCAH, nonclassical congenital adrenal hyperplasia; PCOS, polycystic ovary syndrome. 
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not seem appropriate since, at least in this laboratory, hyper-
androgenism would have remained unidentified in the majority 
of hirsute women. In our opinion there is no rationale to continue 
systematic screening with total testosterone. The possible con-
cern of missing androgen-secreting tumors, a diagnosis that is 
traditionally based on the demonstration of strongly elevated 
total testosterone levels, is not justified since similarly elevated 
salivary testosterone levels, with similar diagnostic relevance, 
TABLE 13. Antiandrogenic Treatment in Patients With Hirsutism, Present and Previous Reports 
First Author, Year Ref. 
8 
24 
No. of 
Patients 
15 
34 
EE and high-dose CA 
Baxendale, 1983 
Holdaway, 1985 
Spritzer, 2000 57 9 PCOS 
Present study 
EE and low-dose CA 
14 IH 
30 
Luque-Ramirez, 2007 34 15 
$ahin, 2001 54 16 
Tartagni, 2000 60 10 PCOS 
15 IH 
Finasteride, EE, and low-dose CA 
$ahin, 2001 54 18 
Tartagni, 2000 60 10 PCOS 
15 IH 
Spironolactone and OC 
Azziz, 2004 6 123 
Flutamide and OC 
Castelo-Branco, 2008 10 58 
Spironolactone 
Ashraf Ganie, 2004 34 
Moghetti, 2000 40 10 
Spritzer, 2000 57 9 PCOS 
11 IH 
Flutamide 
Castelo-Branco, 2008 10 25 
Gambineri, 2004 20 9 
Ibâilez, 2002 25 10 
Moghetti, 2000 40 10 
Finasteride 
Moghetti, 2000 40 10 
Metformin 
Ashraf Ganie, 2004 
Gambineri, 2004 20 
Ibâilez, 2002 25 
Luque-Ramirez, 2007 34 
Metformin and flutamide 
Gambineri, 2004 20 
Ibailez, 2002 25 
35 
10 
8 
12 
10 
13 
Mean Values on Treatment (% of Baseline) 
Hirsutism Score T FT Ts A DHEAS 
Antiandrogens and hormone suppression 
60.0 
54.5 
56.5 
53.5 
67.0t 
62.8 
60.0t 
62.8t 
51.l 
54.5t 
50.0t 
40.9 
54.5 
67.4 
59.2t 
76.2 
66.7 
53.4 
72.7t 
55.3 
63.4t 
70.6t 
80.0 
92.6t 
68.9 
88.2t 
66.7t 
55.5 
60.0 
49.0 
70.0 
66.6 
75.0 
106.6 
45.0 
36.0t 
48.2 
34.2 
48.6 
64.5 
26.7 
41.6 
Antiandrogens only 
54.3 
100.0 
100.0 
98.8 
72.5 73.5 
71.3 
82.7 
121.1 
Insulin sensitizers 
59.5 
72.5 
49.3 
53.6 
51.0 
73.5 
70.8t 
38.6 
45.9 
46 
74 
61 
100 
56.5 
57.0t 
76.3 
77.8 
85.7 
71.4 
100.0 
100.0 
107.9 
85.3 
100 
71.0 
72.0t 
75.5 
75.6 
48.4 
80.7 
71.8 
44.0 
89.9 
107.3 
126.9 
98.3 
68.8 
87.3 
87.4 
107.9 126.9 
86.3 83.3 
85.7t 119.0t 
67.5 70.3 
56.2 57.5 
*Severe side effects required discontinuation of treatment. 
tFigures estimated from graphies. 
tFlutamide only or with OC. 
Side Effects* 
(% of Patients) 
Mild Severe 
64.7 
22.2 
14.3 
23.0 
0.0 
10.0 
10.0 
0.0 
20.0 
20.0 
36.0 
41.0 
26.5 
50.0 
40.0 
45.5 
25.0 
10.0 
0.1 
22.9 
10.0 
12.5 
20.0 
15.4 
11.8 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
10.0t 
2.9 
0.0 
0.0 
0.0 
10.0t 
0.0 
0.0 
11.4 
0.0 
0.0 
10.5 
0.0 
0.0 
Treatment 
(mo) 
3 
9 
12 
12 
12 
6 
12 
6 
6 
12 
6 
6 
12 
6 
6 
12 
12 
6 
9 
6 
6 
6 
6 
9 
6 
6 
9 
Abbreviations: EE, ethinylestradiol; CA, cyproterone acetate; OC, oral contraceptive; PCOS, polycystic ovary syndrome; IH, idiopathie hirsutism. 
For other abbreviations, see previous tables. 
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would probably be found, as illustrated by the 2 patients with 
ovarian tumor in the current study. 
Measuring free testosterone or bioavailable testosterone has 
been proposed as a sensitive adjunct to measming total testoste-
rone when necessary for the evaluation of hyperandrogenism, 36 
but the existing methods have several drawbacks. Testosterone 
circulates in plasma unbound (free, approximately 2%), bound 
to the specific plasma protein SHBG, and weakly bound to 
nonspecific proteins such as albumin. The SHBG-bound fraction 
is biologically inactive because of the high binding affinity of 
SHBG for testosterone. Free testosterone measures the free 
fraction, bioavailable testosterone includes free plus weakly 
bound to albumin. The gold standard for trne plasma free 
testosterone measurement is equilibrium dialysis,51 but this 
expensive and cumbersome technique has no place in a clinical 
setting. Therefore, plasma free testosterone is either measured 
with direct radioimmunoassay or calculated from total testoster-
one and SHBG values, whereas calculated bioavailable 
testosterone also includes albumin. In a previous study we 
showed that direct plasma free testosterone by radioimmunoas-
say was not representative of true free testosterone under 
changing conditions of binding proteins.48 On the other hand, 
calculated free testosterone is influenced by factors that modify 
SHBG levels, including body weight, estrogens, and androgens. 
Therefore, to avoid methodologic pitfalls and confounding fac-
tors, we did not use direct radioimmunoassay or calculated free 
testosterone, but used instead salivary testosterone as an in-
dependent sensitive assay of androgenicity. In the current study, 
salivmy testosterone correlated better to the degree of hirsutism 
than did total testosterone, androstenedione, DHEAS, or SHBG. 
We have previously shown49 that salivaty testosterone 
exceeds calculated free testosterone by a factor of 2 in normal 
women, and by a factor of 3 in hirsute women with identical total 
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testosterone levels, suggesting that salivaty testosterone reflects 
more than a mere passive flux between blood and saliva but ref-
lects also tissue androgen impregnation and action. In addition, 
increased testosterone generation from precursor androstene-
dione in the salivaty glands of hirsute women was inferred 
from studies on the androstenedione-testosterone ratios in plas-
ma and saliva. 59 Our suggestion that saliva was a medium of 
choice to identify patients with hyperandrogenism is sustained 
by the present data on the clinical-biological relationship, and 
we propose that salivary testosterone be considered as a simple 
and the most efficient parameter to screen for androgenization 
in women. 
Diagnosis 
Hyperandrogenic oligo-amenorrheic patients showed sig-
nificantly higher salivmy testosterone and androstenedione than 
hyperandrogenic eumenorrheic patients, while the other hormo-
nal parameters evaluated were not significantly different, 
confirming the highest sensitivity of salivmy testosterone and 
androstenedione to characterize androgenicity in women. 
Patients with hyperandrogenism and oligo-amenorrhea meeting 
the criteria of polycystic ovary syndrome, according to the 
Rotterdam52 and the Androgen Excess Society3 definitions, 
represent 27.6% of all patients in the study, and 39.0% of those 
with hirsutism (see Table 3). This is an underestimate according 
to the Rotterdam criteria, because ovarian morphology, largely 
unavailable, was not taken into account for the diagnosis of 
polycystic ovaty syndrome in this study. In Table 12 we compare 
the prevalence of polycystic ovary syndrome and other specific 
diagnoses in different series of hyperandrogenism. Studies that 
do not take into account ovarian morphology for diagno-
sis,40·53•57 including the present study, repmi a lower prevalence 
of polycystic ovary syndrome than studies that systematically 
-
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FIGURE 1. Comparison of antiandrogenic treatments for hirsutism in present and previous studies, from Table 13. Each bar represents 
the mean hirsutism score on treatment in a study, as a percentage of baseline score as specified in Table 13. The reference number is 
indicated in the bar (references 57 and 60 give separate data on patients with polycystic ovary syndrome and patients with idiopathie 
hirsutism, so they are included twice per relevant treatment). Treatments are displayed in order of their effectiveness in decreasing the 
hirsutism score. To estimate the cost-effectiveness of the different therapies, we calculated the approximate yearly cost of each treatment 
in Switzerland (1 Swiss franc [CHF] "' 1 US dollar). Treatments: A= spironolactone and oral contraceptive (544 CHF); B = finasteride 
plus ethinylestradiol and low-dose cyproterone acetate (343 or 546 CHF, depending on the dose of finasteride); C = flutamide plus 
oral contraceptive (696 CHF); D = ethinylestradiol and high-dose cyproterone acetate, including the present study (440 CHF); 
E = flutamide plus metformin (606 or 11 32 CHF, depending on the dose of flutamide); F = flutamide only (526 or 1052 CHF depending 
on the dose); G = ethinylestradiol and low-dose cyproterone acetate (170 CHF); H = spironolactone only (374 CHF); 1 = finasteride 
only (376 CHF); and J = metformin only (80 CHF). 
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perf01m pelvic ultrasound.9 Studies on clinical hyperandrogen-
ism, including patients with menstrual or ovulat01y abnormalities 
independent of skin symptoms, also show a high prevalence of 
polycystic ovary syndrome.6•16 Although leaving polycystic 
ovary syndrome undiagnosed implies neglecting an increased 
risk ofmetabolic syndrome in these patients, it must be pointed 
out that the inclusion of the ultrasound criteria in the definition of 
polycystic ovary syndrome remains controversial, that the 
presence of polycystic ovarian morphology alone does not 
predict the development ofpolycystic ovaiy syndrome,41 and that 
women with oligo-amenorrhea and polycystic ovarian morphol-
ogy but normal androgens have milder metabolic features of the 
polycystic ovary syndrome. 15 The relatively low number of 
ovarian follicles described in the ultrasound study of our patients 
indicates the poor performance of the transabdominal route, 
which should not be recommended to evaluate polycystic avaries 
whenever transvaginal ultrasonography can be performed. Our 
data also sustain the laclc of usefulness of an elevated LH/FSH 
ratio as a means to identify women with polycystic ovaiy 
syndrome using the present-day gonadotropin assays.39 
Screening for NCAH can be performed by measuring basal 
17-0HP and reserving the cosyntropin test to confirm elevated 
basal levels in a second step. This 2-step procedure would have 
missed NCAH diagnosis in 1 of 4 cases in the current series, and 
would not have confirmed the diagnosis in 17 of 81 other cases. 
Thus, if the clinical setting allows, systematic testing with co-
syntropin should be preferred. The prevalence ofNCAH among 
hyperandrogenic women from central Europe and southern 
Europe was recently found to be 2.7% and 2.2%, respec-
tively, 16•17 lower than that observed in the current study (4 cases 
out of 85 patients with hyperandrogenism undergoing cosyn-
tropin test, or 4.7%). These differences may be more apparent 
than real since, owing to the small numbers, a single positive 
case would considerably change the proportions. However, 
selection bias may have played arole: on the one hand, to qualify 
for hirsutism in the current study, a higher Ferriman and Gallwey 
score was required (score of 9) than in the 2 above-mentioned 
studies (scores of 8 and 7, respectively), and therefore the 
patients we tested had a higher degree of androgenicity. On the 
other band, 2 of our 4 patients originated from the Middle East, 
an area with a higher prevalence ofNCAH than Europe. We note 
that the prevalence ofNCAH in clinical hyperandrogenism was 
4.3% in a large study in Sicily.9 
Although systematic screening was not performed to unveil 
occult Cushing syndrome, none of the patients initially studied 
and followed presented clinically apparent Cushing syndrome as 
a cause of skin or reproductive symptoms. 
Antiandrogenic Treatment 
In Table 13 and Figure 1, we compare different studies 
on antiandrogenic therapy for hirsutism. The antiandrogenic ef-
ficacy of ethinylestradiol and high-dose cyproterone acetate in 
the present study results from both hormone suppression (gona-
dotropins and, subsequently, ovarian androgens) and androgen 
receptor blockade by cyproterone acetate. The role of periph-
eral receptor blockade is underlined by the decrease in the 
hirsutism score with flutamide 10•20 •25 •40 and spironolactone 1•40•57 
only, which are receptor antagonists without gonadotropin sup-
pressive effect, and by the lesser effect of ethinylestradiol and 
low-dose cyproterone acetate (42 mg cyproterone acetate/ 
cycle)34•54•60 compared with ethinylestradiol and high-dose cy-
proterone acetate (550-1100 mg cyproterone acetate/cycle) in 
the present and previous studies,24•57 despite similar gonado-
tropin suppression. The evidence that high-dose cyproterone 
acetate results in no additional benefit on hirsutism compared 
© 2009 Lippincott Williams & Wilkins 
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with low-dose cyproterone acetate is based on only 1 study63 
with relatively small numbers, and it was suggested that the 
effect of larger doses may become apparent in expanded studies. 
The role of dihydrotestosterone on hirsutism is confirmed 
by the efficacy of finasteride, a 5a-reductase inhibitor, which 
appeared similar to flutamide or spironolactone as a single 
drug.40 The role of hormone suppression is demonstrated by 
the more intense effect on hirsutism when ethinylestradiol and 
low-dose cyproterone acetate or other OC combination is add-
ed to antiandrogens or finasteride. 6•10•54•60 Other treatments 
for the skin symptoms of hyperandrogenism have emerged 
in recent years, based on the observation that most women 
with polycystic ovary syndrome are insulin resistant, indepen-
dent of obesity, and based on the assumption that the result-
ing hyperinsulinemia contributes to hyperandrogenemia by 
stimulating androgen synthesis in the ovarian theca cells. 
Therefore, an antiandrogenic effect was expected from lower-
ing insulin levels with insulin sensitizers. In this context, met-
formin is being widely used to treat women with the 
polycystic ovary syndrome desiring fertility. However, as 
shown in Table 13, inconsistent and modest decreases in 
androgenemia are observed with metformin. These may be 
sufficient to contribute to the observed improvement in ovulation 
and fertility,42 but not to induce any relevant effect on hirsutism, 
where antiandrogens are clearly more efficient. 12•58 Conse-
quently, the effect of metformin on hirsutism was also modest 
and inconsistent. 1•20•25 •34 
The available antiandrogenic therapies for hirsutism are 
listed by efficacy in Figure 1, with mention of their respec-
tive costs. Metformin, finasteride, and spironolactone only, and 
ethinylestradiol and low-dose cyproterone acetate, are the least 
expensive and the least effective. Flutamide only was more 
effective on hirsutism than the above drugs, but is considerably 
more expensive. The most prominent effect on hirsutism was 
reported in a study6 with spironolactone and oral contraceptive, 
a treatment with an intermediate cost. With the exception of 
the above study, the ethinylestradiol and high-dose cyprote-
rone acetate used in the current study resulted in a score re-
duction similar to the most efficient and more expensive 
treatments listed. On the other hand, in the current study, 
ethinylestradiol and cyproterone acetate treatment was Jess be-
neficial on alopecia than on hirsutism or acne, corroborating 
the lesser androgen dependence of alopecia. This lesser depen-
dence was the rationale for treating patients with isolated alo-
pecia and normal androgens with spironolactone only, without 
hormone suppression. This less potent therapy was almost as 
effective on isolated alopecia as ethinylestradiol and high-dose 
cyproterone acetate on alopecia with acne or hirsutism. 
Side effects of antiandrogens and hormone suppression 
were typically estrogenic (headache, depression, Joss of libido, 
nausea, breast tenderness, heavy legs, and hypertension), and 
were particularly frequent in the older study listed in Table 13 
(Holdaway et al24 from 1985), which used high ethinylestradiol 
doses (50µ,g/day). Spironolactone was related to inter-menstrual 
bleeding; ethinylestradiol and high-dose cyproterone acetate, 
delayed menstruation; and metformin, gastritis and diarrhea. 
Hyperandrogenemia has been reported to be an indepen-
dent risk factor for the development of the metabolic syndrome 
in women,28 and there could be concern that h01mone therapy 
aggravates the metabolic trend ofthese patients. However, recent 
studies34 show that the association of ethinylestradiol and 
cyproterone acetate (at the low dose ofa contraceptive pill) does 
not result in any worsening of the metabolic profile of women 
with the polycystic ovaiy syndrome, while being more efficient 
than metformin in reducing the hirsutism score. Further studies 
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are necessaty to determine whether higher cyproterone acetate 
doses have any effect on the metabolic profile of these patients, 
and to determine whether hirsutism itself constitutes a metabolic 
risk factor, independent of androgen levels, SHBG levels, and 
the body mass index. 
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